Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear. METHODS: In a randomized, double-blind, noninferiority study, we randomly assigned patients with acute venous thromboembolism, who had initially received heparin, to receive edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g., in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body weight below 60 kg), or to receive warfarin. Patients received the study drug for 3 to 12 months. The primary efficacy outcome was recurrent symptomatic venous thromboembolism. The principal safety outcome was major or clinically relevant nonmajor bleeding. RESULTS: A total of 4921 patients presented with deep-vein thrombosis, and 3319 with a pulmonary embolism. Among patients receiving warfarin, the time in the therapeutic range was 63.5%. Edoxaban was noninferior to warfarin with respect to the primary efficacy outcome, which occurred in 130 patients in the edoxaban group (3.2%) and 146 patients in the warfarin group (3.5%) (hazard ratio, 0.89; 95% confidence interval [CI], 0.70 to 1.13; P<0.001 for noninferiority). The safety outcome occurred in 349 patients (8.5%) in the edoxaban group and 423 patients (10.3%) in the warfarin group (hazard ratio, 0.81; 95% CI, 0.71 to 0.94; P=0.004 for superiority). The rates of other adverse events were similar in the two groups. A total of 938 patients with pulmonary embolism had right ventricular dysfunction, as assessed by measurement of N-terminal pro-brain natriuretic peptide levels; the rate of recurrent venous thromboembolism in this subgroup was 3.3% in the edoxaban group and 6.2% in the warfarin group (hazard ratio, 0.52; 95% CI, 0.28 to 0.98). CONCLUSIONS: Edoxaban administered once daily after initial treatment with heparin was noninferior to high-quality standard therapy and caused significantly less bleeding in a broad spectrum of patients with venous thromboembolism, including those with severe pulmonary embolism. (Funded by Daiichi-Sankyo; Hokusai-VTE ClinicalTrials.gov number, NCT00986154.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
SCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
SCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Self-citationDabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302507 · Cited by 2,324
The Epidemiology of Venous Thromboembolism
White, R. H. (2003) · Circulation · doi:10.1161/01.cir.0000078468.11849.66 · Cited by 2,310
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,065
Pulmonary embolism and deep vein thrombosis
Goldhaber, S. Z., & Bounameaux, H. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61904-1 · Cited by 1,054
Cited by
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Delling, F. N., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000757 · Cited by 9,175
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036
Konstantinides, S. V., Meyer, G., Becattini, C., Bueno, H., Geersing, G.-J., Harjola, V.-P., Huisman, M. V., Humbert, M., Jennings, C. S., Jiménez, D., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz405 · Cited by 4,916
Edoxaban versus warfarin in patients with atrial fibrillation
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310907 · Cited by 5,164
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism
Authors/Task Force Members, Konstantinides, S. V., Torbicki, A., Agnelli, G., Danchin, N., Fitzmaurice, D., Galiè, N., Gibbs, J. S. R., Huisman, M. V., Humbert, M., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu283 · Cited by 3,128
Steffel, J., Verhamme, P., Potpara, T. S., Albaladejo, P., Antz, M., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy136 · Cited by 2,123
Konstantinides, S. V., Meyer, G., Becattini, C., Bueno, H., Geersing, G.-J., Harjola, V.-P., Huisman, M. V., Humbert, M., Jennings, C. S., Jiménez, D., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01647-2019 · Cited by 1,619
“If dabigatran or edoxaban is chosen for extended anticoagulation after PE, the dose should remain unchanged, as reduced-dose regimens were not investigated in dedicated extension trials.(313,350) Especially for patients receiving NOACs.”
BackgroundOrtel, T. L., Neumann, I., Ageno, W., Beyth, R., Clark, N. P., Cuker, A., Hutten, B. A., Jaff, M. R., Manja, V., Schulman, S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001830 · Cited by 1,489
Kaatz, S., Ahmad, D., Spyropoulos, A. C., & Schulman, S. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13140 · Cited by 1,419
Young, A. M., Marshall, A., Thirlwall, J., Chapman, O., Lokare, A., Hill, C., Hale, D., Dunn, J. A., Lyman, G. H., Hutchinson, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.8034 · Cited by 1,348
Steffel, J., Collins, R., Antz, M., Cornu, P., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., Rowell, N., et al. (2021) · EP Europace · doi:10.1093/europace/euab065 · Cited by 1,132
Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Diener, H.-C., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., & Kirchhof, P. (2015) · Europace · doi:10.1093/europace/euv309 · Cited by 1,113
Antithrombotic Therapy for VTE Disease
Stevens, S. M., Woller, S. C., Kreuziger, L. B., Bounameaux, H., Doerschug, K., Geersing, G.-J., Huisman, M. V., Kearon, C., King, C. S., Knighton, A. J., et al. (2021) · Chest · doi:10.1016/j.chest.2021.07.055 · Cited by 1,043
Deep vein thrombosis and pulmonary embolism
Di Nisio, M., van Es, N., & Büller, H. R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30514-1 · Cited by 994
Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis
Schulman, S., Kakkar, A. K., Goldhaber, S. Z., Schellong, S., Eriksson, H., Mismetti, P., Christiansen, A. V., Friedman, J., Le Maulf, F., Peter, N., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.004450 · Cited by 923
Management of severe perioperative bleeding: Guidelines from the European Society of Anaesthesiology
Kozek-Langenecker, S. A., Afshari, A., Albaladejo, P., Santullano, C. A. A., De Robertis, E., Filipescu, D. C., Fries, D., Görlinger, K., Haas, T., Imberger, G., et al. (2013) · European Journal of Anaesthesiology · doi:10.1097/eja.0b013e32835f4d5b · Cited by 909
van Es, N., Coppens, M., Schulman, S., Middeldorp, S., & Büller, H. R. (2014) · Blood · doi:10.1182/blood-2014-04-571232 · Cited by 851
“For Hokusai-VTE, we used event data for the overall study period.(3) The group of patients with impaired renal function includes 28 DOAC recipients and 32 VKA recipients with a creatinine clearance ,30 mL per minute (protocol violations).”
MethodKozek-Langenecker, S. A., Ahmed, A. B., Afshari, A., Albaladejo, P., Aldecoa, C., Barauskas, G., De Robertis, E., Faraoni, D., Filipescu, D. C., Fries, D., et al. (2017) · European Journal of Anaesthesiology · doi:10.1097/eja.0000000000000630 · Cited by 800
Kakkos, S. K., Gohel, M., Baekgaard, N., Bauersachs, R., Bellmunt-Montoya, S., Black, S. A., ten Cate-Hoek, A. J., Elalamy, I., Enzmann, F. K., Geroulakos, G., et al. (2021) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2020.09.023 · Cited by 743
Frontera, J. A., Lewin III, J. J., Rabinstein, A. A., Aisiku, I. P., Alexandrov, A. W., Cook, A. M., del Zoppo, G. J., Kumar, M. A., Peerschke, E. I. B., Stiefel, M. F., et al. (2016) · Neurocritical Care · doi:10.1007/s12028-015-0222-x · Cited by 706
ATUALIZAÇÃO DA DIRETRIZ BRASILEIRA DE DISLIPIDEMIAS E PREVENÇÃO DA ATEROSCLEROSE - 2017
Faludi, A., Izar, M., Saraiva, J., Chacra, A., Bianco, H., Afiune Neto, A., Bertolami, A., Pereira, A., Lottenberg, A., Sposito, A., et al. (2017) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20170121 · Cited by 633
Farge, D., Frere, C., Connors, J. M., Ay, C., Khorana, A. A., Munoz, A., Brenner, B., Kakkar, A., Rafii, H., Solymoss, S., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30336-5 · Cited by 651
Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019
Moores, L. K., Tritschler, T., Brosnahan, S., Carrier, M., Collen, J. F., Doerschug, K., Holley, A. B., Jimenez, D., Le Gal, G., Rali, P., et al. (2020) · Chest · doi:10.1016/j.chest.2020.05.559 · Cited by 638
Task Force Members, Lip, G. Y. H., Windecker, S., Huber, K., Kirchhof, P., Marin, F., Ten Berg, J. M., Haeusler, K. G., Boriani, G., Capodanno, D., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu298 · Cited by 566
“3%) (see Supplementary material online, Table w2).(76)”
Epidemiology and prevention of venous thromboembolism
Lutsey, P. L., & Zakai, N. A. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00787-6 · Cited by 507
van der Hulle, T., Kooiman, J., den Exter, P. L., Dekkers, O. M., Klok, F. A., & Huisman, M. V. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12485 · Cited by 536
Mismetti, P., Laporte, S., Pellerin, O., Ennezat, P.-V., Couturaud, F., Elias, A., Falvo, N., Meneveau, N., Quere, I., Roy, P.-M., et al. (2015) · JAMA · doi:10.1001/jama.2015.3780 · Cited by 489
Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH
Martin, K., Beyer‐Westendorf, J., Davidson, B. L., Huisman, M. V., Sandset, P. M., & Moll, S. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13323 · Cited by 445
Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Akl, E. A., Kahale, L. A., Barba, M., Neumann, I., Labedi, N., Terrenato, I., Sperati, F., Muti, P., & Schünemann, H. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006650.pub4 · Cited by 428
Use of PER977 to Reverse the Anticoagulant Effect of Edoxaban
Ansell, J. E., Bakhru, S. H., Laulicht, B. E., Steiner, S. S., Grosso, M., Brown, K., Dishy, V., Noveck, R. J., & Costin, J. C. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1411800 · Cited by 419
Mekaj, A., Mekaj, Y., Duci, S., & Miftari, E. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s84210 · Cited by 407
Deep vein thrombosis: pathogenesis, diagnosis, and medical management
Stone, J., Hangge, P., Albadawi, H., Wallace, A., Shamoun, F., Knuttien, M. G., Naidu, S., & Oklu, R. (2017) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2017.09.01 · Cited by 381
“After more than a decade of research, multiple large-scale clinical trials have demonstrated comparable efficacy between the two drug classes (46,50,52,57,58,61,63).”
BackgroundResultGosselin, R., Adcock, D., Bates, S., Douxfils, J., Favaloro, E., Gouin-Thibault, I., Guillermo, C., Kawai, Y., Lindhoff-Last, E., & Kitchen, S. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1627480 · Cited by 392
Wolberg, A. S., Rosendaal, F. R., Weitz, J. I., Jaffer, I. H., Agnelli, G., Baglin, T., & Mackman, N. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.6 · Cited by 369
Management of venous thrombo-embolism: an update
Konstantinides, S., & Torbicki, A. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu243 · Cited by 383
“The most recently published study, Hokusai-VTE, compared the direct factor Xa inhibitor edoxaban with conventional therapy in 8240 patients with VTE who had initially received heparin for at least 5 days.(53) Patients received edoxaban at a dose of 60 mg once daily (reduced to 30 mg once daily in the case of creatinin…”
MethodVenous Thromboembolism: Advances in Diagnosis and Treatment
Tritschler, T., Kraaijpoel, N., Le Gal, G., & Wells, P. S. (2018) · JAMA · doi:10.1001/jama.2018.14346 · Cited by 357
Guidance for the treatment of deep vein thrombosis and pulmonary embolism
Streiff, M. B., Agnelli, G., Connors, J. M., Crowther, M., Eichinger, S., Lopes, R., McBane, R. D., Moll, S., & Ansell, J. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1317-0 · Cited by 344
“Edoxaban was compared with warfarin in the treatment of VTE in the HOKUSAI-VTE study, a large randomized double-blind non-inferiority study conducted in 8292 patients enrolled in 439 centers in 37 countries [46].”
BackgroundMethodHuisman, M. V., Barco, S., Cannegieter, S. C., Le Gal, G., Konstantinides, S. V., Reitsma, P. H., Rodger, M., Noordegraaf, A. V., & Klok, F. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.28 · Cited by 336
Farge, D., Bounameaux, H., Brenner, B., Cajfinger, F., Debourdeau, P., Khorana, A. A., Pabinger, I., Solymoss, S., Douketis, J., & Kakkar, A. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30369-2 · Cited by 347
Male, C., Lensing, A. W. A., Palumbo, J. S., Kumar, R., Nurmeev, I., Hege, K., Bonnet, D., Connor, P., Hooimeijer, H. L., Torres, M., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30219-4 · Cited by 339
Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment
Burnett, A. E., Mahan, C. E., Vazquez, S. R., Oertel, L. B., Garcia, D. A., & Ansell, J. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1310-7 · Cited by 333
“In clinical trials of edoxaban and dabigatran [6, 10] initial treatment consisted of open-label parenteral anticoagulation (median of 9 and 7 days in the dabigatran and edoxaban trials, respectively) overlapped with warfarin titrated to an INR of 2–3 in the control arm or overlapped with warfarin-placebo titrated to a…”
MethodManagement of Pulmonary Embolism
Konstantinides, S. V., Barco, S., Lankeit, M., & Meyer, G. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.11.061 · Cited by 330
Chai-Adisaksopha, C., Crowther, M., Isayama, T., & Lim, W. (2014) · Blood · doi:10.1182/blood-2014-07-590323 · Cited by 326
Acute Pulmonary Embolism: A Review
Freund, Y., Cohen-Aubart, F., & Bloom, B. (2022) · JAMA · doi:10.1001/jama.2022.16815 · Cited by 301
Erkan, D., Aguiar, C. L., Andrade, D., Cohen, H., Cuadrado, M. J., Danowski, A., Levy, R. A., Ortel, T. L., Rahman, A., Salmon, J. E., et al. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.01.053 · Cited by 322
Left Ventricular Thrombus After Acute Myocardial Infarction: Screening, Prevention, and Treatment
McCarthy, C. P., Vaduganathan, M., McCarthy, K. J., Januzzi, J. L., Bhatt, D. L., & McEvoy, J. W. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.1086 · Cited by 268
Direct Oral Anticoagulants in Patients With VTE and Cancer
Vedovati, M. C., Germini, F., Agnelli, G., & Becattini, C. (2015) · Chest · doi:10.1378/chest.14-0402 · Cited by 270
Diagnosis and Treatment of Lower Extremity Venous Thromboembolism: A Review
Chopard, R., Albertsen, I. E., & Piazza, G. (2020) · JAMA · doi:10.1001/jama.2020.17272 · Cited by 244
Zahir, H., Brown, K. S., Vandell, A. G., Desai, M., Maa, J.-F., Dishy, V., Lomeli, B., Feussner, A., Feng, W., He, L., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.013445 · Cited by 252
“has demonstrated safety and efficacy in the prevention of stroke in patients with atrial fibrillation(2) and in the treatment and secondary prevention of venous thromboembolism.(3)”
BackgroundCouturaud, F., Sanchez, O., Pernod, G., Mismetti, P., Jego, P., Duhamel, E., Provost, K., dit Sollier, C. B., Presles, E., Castellant, P., et al. (2015) · JAMA · doi:10.1001/jama.2015.7046 · Cited by 249
Pulmonary embolism: update on management and controversies
Duffett, L., Castellucci, L. A., & Forgie, M. A. (2020) · BMJ · doi:10.1136/bmj.m2177 · Cited by 232
NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018
Streiff, M. B., Holmstrom, B., Angelini, D., Ashrani, A., Bockenstedt, P. L., Chesney, C., Fanikos, J., Fenninger, R. B., Fogerty, A. E., Gao, S., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0084 · Cited by 242
Sharma, M., Cornelius, V. R., Patel, J. P., Davies, J. G., & Molokhia, M. (2015) · Circulation · doi:10.1161/circulationaha.114.013267 · Cited by 243
“In particular, dabigatran was associated with a higher risk of gastrointestinal bleeding than VKA.”
MethodInfluentialAgeno, W., Mantovani, L. G., Haas, S., Kreutz, R., Monje, D., Schneider, J., van Eickels, M., Gebel, M., Zell, E., & Turpie, A. G. G. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00257-4 · Cited by 243
Treatment of Venous Thromboembolism
Wells, P. S., Forgie, M. A., & Rodger, M. A. (2014) · JAMA · doi:10.1001/jama.2014.65 · Cited by 237
Smythe, M. A., Priziola, J., Dobesh, P. P., Wirth, D., Cuker, A., & Wittkowsky, A. K. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1315-2 · Cited by 231
“0 (see above and Table 3) [11] When dabigatran or edoxaban are used for VTE treatment, LMWH must be started first and continued for a minimum of 5 days prior to initiation of these oral anticoagulants [47, 49, 50].”
BackgroundMethodParasrampuria, D. A., & Truitt, K. E. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0342-7 · Cited by 229
Posch, F., Königsbrügge, O., Zielinski, C., Pabinger, I., & Ay, C. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.07.011 · Cited by 215
“Recently, direct-acting oral anticoagulants (DOACs) that directly inhibit either factor Xa (apixaban, edoxaban, and rivaroxaban) or thrombin (dabigatran) have been introduced as novel agents for treatment of VTE [11–14].”
BackgroundNew Oral Anticoagulants and the Cancer Patient
Short, N. J., & Connors, J. M. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0239 · Cited by 204
Sterne, J. A., Bodalia, P. N., Bryden, P. A., Davies, P. A., López-López, J. A., Okoli, G. N., Thom, H. H., Caldwell, D. M., Dias, S., Eaton, D., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21090 · Cited by 198
Cohen, A. T., Hamilton, M., Mitchell, S. A., Phatak, H., Liu, X., Bird, A., Tushabe, D., & Batson, S. (2015) · PLOS ONE · doi:10.1371/journal.pone.0144856 · Cited by 198
“Recurrent VTE included fatal or non-fatal PE and DVT; RE-COVER [24]–composite of VTE or death associated with VTE; RE-COVER II [22]–VTE or VTE-related death; EINSTEIN DVT [19], EINSTEIN PE [20] and Hokusai-VTE [23]–composite of DVT and non-fatal or fatal PE.”
BackgroundMethodResultInfluentialTrousseau's syndrome: cancer-associated thrombosis
Ikushima, S., Ono, R., Fukuda, K., Sakayori, M., Awano, N., & Kondo, K. (2016) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyv165 · Cited by 199
Chai‐Adisaksopha, C., Hillis, C., Isayama, T., Lim, W., Iorio, A., & Crowther, M. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13139 · Cited by 190
Deep vein thrombosis: update on diagnosis and management
Kruger, P. C., Eikelboom, J. W., Douketis, J. D., & Hankey, G. J. (2019) · Medical Journal of Australia · doi:10.5694/mja2.50201 · Cited by 188
Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes
Khairani, C. D., Bejjani, A., Piazza, G., Jimenez, D., Monreal, M., Chatterjee, S., Pengo, V., Woller, S. C., Cortes-Hernandez, J., Connors, J. M., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.10.008 · Cited by 172
Yaghi, S. R., Shu, L., Bakradze, E., Omran, S. S., Giles, J. A., Amar, J. Y., Henninger, N., Elnazeir, M., Liberman, A. L., Moncrieffe, K., et al. (2022) · Stroke · doi:10.1161/strokeaha.121.037541 · Cited by 190
“(3) Safety outcomes: Major hemorrhage defined as new or worsening intracranial hemorrhage or major extracranial hemorrhage defined as systemic hemorrhage with at least 2 g/dL drop in hemoglobin level or requiring blood transfusion occurring while on oral anticoagulation therapy.”
BackgroundCarrier, M., Cameron, C., Delluc, A., Castellucci, L., Khorana, A. A., & Lee, A. Y. Y. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.09.039 · Cited by 172
Almutairi, A. R., Zhou, L., Gellad, W. F., Lee, J. K., Slack, M. K., Martin, J. R., & Lo-Ciganic, W.-H. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.05.358 · Cited by 171
Review of the cost of venous thromboembolism
Fernandez, M., Hogue, S. L., Preblick, R., & Kwong, W. J. (2015) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s85635 · Cited by 171
Lankeit, M., Jiménez, D., Kostrubiec, M., Dellas, C., Kuhnert, K., Hasenfuß, G., Pruszczyk, P., & Konstantinides, S. (2014) · European Respiratory Journal · doi:10.1183/09031936.00211613 · Cited by 170
Cohen, H., Cuadrado, M. J., Erkan, D., Duarte‐García, A., Isenberg, D. A., Knight, J. S., Ortel, T. L., Rahman, A., Salmon, J. E., Tektonidou, M. G., et al. (2020) · Lupus · doi:10.1177/0961203320950461 · Cited by 181
Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism
Witt, D. M., Clark, N. P., Kaatz, S., Schnurr, T., & Ansell, J. E. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1319-y · Cited by 161
“However, no difference in major bleeding was evident when dabigatran (although there was less overall bleeding) and edoxaban (showed less major plus clinically relevant non-major bleeding) when compared to warfarin-based VTE therapy [15, 18].”
BackgroundResultCastellucci, L. A., Cameron, C., Le Gal, G., Rodger, M. A., Coyle, D., Wells, P. S., Clifford, T., Gandara, E., Wells, G., & Carrier, M. (2014) · JAMA · doi:10.1001/jama.2014.10538 · Cited by 162
Dufrost, V., Risse, J., Reshetnyak, T., Satybaldyeva, M., Du, Y., Yan, X.-X., Salta, S., Gerotziafas, G., Jing, Z.-C., Elalamy, I., et al. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.04.009 · Cited by 161
Raskob, G. E., van Es, N., Segers, A. E. M., Angchaisuksiri, P., Oh, D., Boda, Z., Lyons, R. M., Meijer, K., Gudz, I., Weitz, J. I., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)30057-6 · Cited by 167
Barco, S., Schmidtmann, I. M., Ageno, W., Bauersachs, R. M., Becattini, C., Bernardi, E., Beyer‐Westendorf, J., Bonacchini, L., Brachmann, J., Christ, M., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz367 · Cited by 184
“The most frequent sites of major bleeding in HoT-PE, notably gastrointestinal and uterine bleeding, are in line with the results of previous trials on coagulation factor Xa inhibitors.(20,24) Clearly, any comparisons between the results of this and previous studies should be interpreted with caution in view of the dif…”
Resultvan der Hulle, T., den Exter, P. L., Kooiman, J., van der Hoeven, J. J. M., Huisman, M. V., & Klok, F. A. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12605 · Cited by 164
Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer
Kahale, L. A., Hakoum, M. B., Tsolakian, I. G., Alturki, F., Matar, C. F., Terrenato, I., Sperati, F., Barba, M., Yosuico, V. E. D., Schünemann, H. J., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006650.pub5 · Cited by 170
Schrag, D., Uno, H., Rosovsky, R. P. G., Rutherford, C., Sanfilippo, K. M., Villano, J. L., Drescher, M. R., Jayaram, N. H., Holmes, C. E., Feldman, L. E., et al. (2023) · JAMA · doi:10.1001/jama.2023.7843 · Cited by 166
Yamashita, Y., Morimoto, T., Amano, H., Takase, T., Hiramori, S., Kim, K., Konishi, T., Akao, M., Kobayashi, Y., Inoue, T., et al. (2018) · Circulation Journal · doi:10.1253/circj.cj-17-1128 · Cited by 156
Reversal of anticoagulants: an overview of current developments
Thiele, T., Selleng, K., & Greinacher, A. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-11-0982 · Cited by 161
Laboratory Monitoring of Direct Oral Anticoagulants (DOACs)
Dunois-Lardé, C. (2021) · Biomedicines · doi:10.3390/biomedicines9050445 · Cited by 174
Nagaoki, Y., Aikata, H., Daijo, K., Teraoka, Y., Shinohara, F., Nakamura, Y., Hatooka, M., Morio, K., Nakahara, T., Kawaoka, T., et al. (2017) · Hepatology Research · doi:10.1111/hepr.12895 · Cited by 156
“Two recent studies [29, 30] concluded that edoxaban (administered once daily after initial treatment with heparin) can be an alternative to warfarin in patients with”
BackgroundAgnelli, G., Becattini, C., Bauersachs, R., Brenner, B., Campanini, M., Cohen, A., Connors, J., Fontanella, A., Gussoni, G., Huisman, M., et al. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1668523 · Cited by 146
Cohen, H., Arachchillage, D. J., Middeldorp, S., Beyer‐Westendorf, J., & Kadir, R. A. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13366 · Cited by 154
Fuji, T., Wang, C., Fujita, S., Kawai, Y., Nakamura, M., Kimura, T., Ibusuki, K., Ushida, H., Abe, K., & Tachibana, S. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.09.011 · Cited by 143
“Edoxaban is a novel, oral, direct factor Xa inhibitor that has been evaluated for stroke prevention in atrial fibrillation aswell as treatment and secondary prevention of recurrent VTE [5,6].”
BackgroundKakkos, S. K., Kirkilesis, G. I., & Tsolakis, I. A. (2014) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2014.05.001 · Cited by 138
Miller, C., Dorreen, A. P., Martel, M., Huynh, T. T., & Barkun, A. N. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.04.031 · Cited by 149
“Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation.”
InfluentialGómez‐Outes, A., Terleira‐Fernández, A. I., Lecumberri, R., Suárez‐Gea, M. L., & Vargas, E. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.06.020 · Cited by 148
Andreozzi, G. M., Bignamini, A. A., Davì, G., Palareti, G., Matuška, J., Holý, M., Pawlaczyk-Gabriel, K., Džupina, A., Юрьевич, С. Г., Didenko, Y. P., et al. (2015) · Circulation · doi:10.1161/circulationaha.115.016930 · Cited by 138
Lutz, J., Jurk, K., & Schinzel, H. (2017) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s105771 · Cited by 143
“Edoxaban had a trend toward higher efficacy in this patient group in the HOKUSAI-VTE trial, while its safety was not affected by age.(51) Data regarding age and renal function in both trials are not available so far.”
A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension
Bunclark, K., Newnham, M., Chiu, Y., Ruggiero, A., Villar, S. S., Cannon, J. E., Coghlan, G., Corris, P. A., Howard, L., Jenkins, D. P., et al. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14649 · Cited by 143
Marbury, T. C., Matsushima, N., Chen, S., Wickremasingha, P. K., He, L., Dishy, V., Brown, K. S., & Parasrampuria, D. A. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-06-0547 · Cited by 135
Elsebaie, M. A., van Es, N., Langston, A. A., Buller, H. R., & Gaddh, M. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14398 · Cited by 142
Update on Guidelines for the Management of Cancer-Associated Thrombosis
Streiff, M. B., Abutalib, S. A., Farge, D., Murphy, M. C., Connors, J. M., & Piazza, G. (2020) · The Oncologist · doi:10.1002/onco.13596 · Cited by 143
Evolving use of new oral anticoagulants for treatment of venous thromboembolism
Yeh, C. H., Gross, P. L., & Weitz, J. I. (2014) · Blood · doi:10.1182/blood-2014-03-563056 · Cited by 127
“Although the mortality rates in PE patients with and without right ventricular dysfunction were similar in the Hokusai-VTE trial, the superiority of edoxaban in patients with right ventricular dysfunction supports the effectiveness of edoxaban for VTE treatment.(19)”
ResultEdoxaban: a focused review of its clinical pharmacology
Lip, G. Y. H., & Agnelli, G. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu181 · Cited by 126
Ballestri, S., Romagnoli, E., Arioli, D., Coluccio, V., Marrazzo, A., Athanasiou, A., Girolamo, M. D., Cappi, C., Marietta, M., & Capitelli, M. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02333-9 · Cited by 150
“Data from RCTs In RCTs of DOACs on patients with VTE (RE-COVER, EINSTEIN-DVT, EINSTEIN-PE, AMPLIFY, Hokusai-VTE), the risk of MB was significantly lower with rivaroxaban (HR 0.54) and apixaban (HR 0.31), while it was similar with dabigatran 150 mg and edoxaban compared to warfarin; cases of ICH were lower with all fou…”
BackgroundInfluentialStubbs, M. J., Mouyis, M., & Thomas, M. R. (2018) · BMJ · doi:10.1136/bmj.k351 · Cited by 151
Metadata
- Authors
- The Hokusai-VTE Investigators
- Corresponding author
- The Hokusai-VTE Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-10-10
- Volume
- 369
- Issue
- 15
- Pages
- 1406-1415
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2160625453
- Cited by
- 1,869
- References
- 25
- Citations by year
- 2026: 52 · 2025: 75 · 2024: 112 · 2023: 104 · 2022: 116 · 2021: 128 · 2020: 179 · 2019: 170 · 2018: 190 · 2017: 173 · 2016: 210 · 2015: 173 · 2014: 161 · 2013: 25
- FWCI
- 165.78
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- IRIS (submittedVersion)
- Institutional Research Information System (Università degli Studi di Trento) (submittedVersion)
- Iris (University of Trento) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Sanofi
- Daiichi-Sankyo
- LEO Pharma
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- warfarin, venous thromboembolism, factor Xa inhibitors, deep vein thrombosis, pulmonary embolism, recurrent venous thromboembolism, non-inferiority, bleeding risk, right ventricular dysfunction, N-terminal pro-brain natriuretic peptide, anticoagulation, heparin, renal dysfunction, body weight
- MeSH terms
- Aged, Anticoagulants, Double-Blind Method, Drug Administration Schedule, Female, Hemorrhage, Humans, Male, Middle Aged, Pulmonary Embolism, Warfarin, Enoxaparin, Kaplan-Meier Estimate, Venous Thromboembolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.